Hormonal
A high baseline Triglyceride-Glucose (TyG) index, calculated as ln[fasting triglycerides (mg/dL) * FPG (mg/dL) / 2], is a strong independent predictor of incident type 2 diabetes, with individuals in the highest quartile facing a >4-fold higher risk compared to the lowest quartile.
If you are concerned about your risk for type 2 diabetes, ask your doctor to calculate your TyG index using your fasting triglyceride and fasting glucose levels. This simple calculation is a more sensitive early warning system than standard glucose tests alone, especially if you have normal glucose levels but elevated triglycerides. A high result indicates higher insulin resistance and warrants lifestyle interventions to prevent diabetes.
After adjusting for age, gender, body mass index, waist circumference, systolic blood pressure, high-density lipoprotein (HDL)-cholesterol level, a family history of diabetes, smoking, alcohol drinking, education level and serum insulin level, the risk of diabetes onset was more than fourfold higher in the highest vs. the lowest quartile of the TyG index (relative risk, 4.095; 95% CI, 2.701–6.207).
Why this rating
Large prospective cohort study (n=5,354) with long-term follow-up (median 4.6 years) and rigorous adjustment for confounders.
Source
Predicting the Development of Diabetes Using the Product of Triglycerides and Glucose: The Chungju Metabolic Disease Cohort (CMC) Study
Seung‐Hwan Lee et al. · PLoS ONE · 2014
DOI 10.1371/journal.pone.0090430
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →